ClinicalTrials.gg
RecruitingNCT06406621Updated Oct 14, 2026

Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker Skin Color

An interventional study of Laser hair depilation and Standard of Care (SOC) in Pilonidal Disease, sponsored by Nemours Children's Clinic. Recruiting at 1 site in United States. Open to participants aged 10 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Nemours Children's Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 14, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
10 Years to 21 Years
Sex
All
01

Study summary

Pilot randomized trial assessing the effectiveness of laser hair depilation on pilonidal disease recurrence in patients with darker skin color

Read the detailed description

Pilonidal disease is a painful skin infection that occurs in the crease of the buttocks near the tailbone (gluteal cleft) and affects approximately 1% of the population between the ages of 15-30 years. Medical therapy of pilonidal disease is largely dependent upon continued hair removal, meticulous hygiene to the area, and recurrent courses of antibiotics with intermittent incision and drainage procedures. However, recurrent pilonidal disease after initial incision and drainage can be as high as 40% and wound complications after resection have been reported to be as high as 30%. Recurrence often leads to a substantial burden on patients with dependence on caregivers, long term disability, reduced quality of life, and social withdrawal.

Chronic hair removal to the gluteal cleft is a consistently recommended therapy to prevent pilonidal disease recurrence. Research has demonstrated the efficacy of laser hair depilation of the gluteal cleft to reduce pilonidal disease recurrence compared to standard of care in adult and adolescents. A recent randomized controlled trial (RCT) demonstrated laser hair depilation significantly decreased recurrence rates at 1 year from 33% to 10%. However, in exploratory secondary analyses, there was potential heterogeneity of treatment effect based on self-reported race and ethnicity. Although limited by small numbers of patients in many of the racial and ethnic groups, there was a significant reduction in disease recurrence among Non-Hispanic White patients with laser treatment but no change in recurrence among all other groups.

This study will investigate the effects of laser hair depilation on pilonidal disease recurrence among those with darker skin types. We will perform a pilot RCT comparing laser hair depilation and mechanical/chemical depilation (intervention group) to mechanical/chemical depilation alone (control group). The rate of recurrence of pilonidal disease at 1 year will be compared between the two groups. This pilot study will generate the efficacy estimates needed to design a multicenter RCT to provide definitive evidence to support equitable inclusion of laser hair depilation as a treatment adjunct for pilonidal disease. We hypothesize that laser hair depilation will lead to lower rates of disease recurrence at 1-year follow-up compared to standard of care. We will also compare differences in the 1-year morbidity associated with pilonidal disease between the two groups. We hypothesize that laser hair depilation will lead to less morbidity including less disability, higher health related quality of life, higher healthcare satisfaction, and fewer procedures, surgical excisions, and post-operative complications.

This is an exploratory pilot trial aimed at generating an effect size to inform the design of a larger confirmatory study with formal hypothesis testing. The recurrence rate within 1 year is expected to be 30% in the control group, while it is unknown in the laser group, with an expectation of a substantially lower rate in this group. A sample size of 30 patients (15 in each group) can detect an absolute reduction of 29% in the recurrence rate in the laser group compared to the control group, with a power of 80% at a significance level of 0.05. However, we anticipate a minimum reduction of 10% in the recurrence rate in the laser group. The planned sample size of 30 patients will yield a two-sided 95% confidence interval with a precision of 0.31 (half-width) to estimate this difference when the recurrence rate is 30% in the control group and 20% in the laser group. Assuming an attrition rate of 20%, we plan a sample size of 36 (18+18).

The estimate of the efficacy of laser hair removal to decrease pilonidal disease recurrence in darker skin adolescents/young adults from this pilot study is needed to design and perform a critical multi-institutional trial. A focused study of laser hair depilation in patients with darker skin types is essential to promote equitable health care across all patients with pilonidal disease by targeted inclusion of underrepresented populations with darker skin types in a therapeutic trial. Community engagement and partnership with Delaware communities that represent these populations will be critical to engage these underrepresented populations in research and to disseminate and implement research findings into these communities.

02

Conditions studied

  • Pilonidal Disease

Keywords

  • laser hair depilation
  • pilonidal
03

In context

Lead sponsor

Nemours Children's Clinic is the lead sponsor of 130 studies on the registry; 26 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 10-21 years
  • Diagnosis of pilonidal disease
  • Fitzpatrick skin type IV, V, or VI

Exclusion criteria

Exclusion Criteria:

  • History of photosensitivity
  • Actively inflamed pilonidal sinus (will be offered enrollment upon resolution).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    Standard Care

    Will be provided with the "best recommended standard of care" based on recommendations from published studies and guidelines2,10,13,25,26 including educating on the importance and application of chronic hair removal to provide a standardized education and training to all patients in the control group. They will have the option to schedule additional in-person visits for further education and training on hair removal.

    Other: Standard of Care (SOC)

  • Experimental
    Laser group

    Description: Laser hair depiction treatment with Nd:YAG laser every 4-6 weeks until 90% hair reduction is achieved as determined by clinical evaluation. Similar to the control group, they will also receive the "best recommended standard care" including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments.

    Procedure: Laser hair depilation

Interventions

  • ProcedureLaser hair depilation

    Laser hair depilation treatment with Nd:YAG laser every 4-6 weeks until 90% hair reduction is achieved as determined by clinical evaluation. Similar to the control group, they will also receive the "best recommended standard care" including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments.

    Also known as: laser hair removal, laser epilation

  • OtherStandard of Care (SOC)

    The control group will be provided with the "best recommended standard of care" based on recommendations from published studies and guidelines7,31-34 including educating on the importance and application of chronic hair removal to provide a standardized education and training to all patients in the control group. Patients and families in the control group will be taught hair removal techniques and the technique of mechanical depilation will be demonstrated for the patient and caregiver with the nurse or physician shaving the gluteal cleft of the patient during this visit. It will be recommended that they perform either chemical (cream application as directed) or mechanical depilation (shaving) as needed to keep the area hair free. The choice between chemical or mechanical depilation is up to the patient and family.

06

What researchers measure

Primary outcomes

  1. Disease Recurrence

    Disease recurrence is defined as development of a new pilonidal abscess, folliculitis, or draining sinus after treatment, which would require antibiotic therapy, additional surgical incision and drainage, or excision. development of an abscess, folliculitis, or draining sinus which requires treatment (antibiotic therapy, surgical incision and drainage, or excision).

    Time frame: 1 year

Secondary outcomes

  1. Disability days

    Disability days will be defined as all days in which the patient was not able to participate in all normal activities secondary to pilonidal disease within 1 year.

    Time frame: 1 year

  2. health-related quality of life (HRQOL) and healthcare satisfaction

    The PedsQLTM Quality of Life Inventory: Child and Parent Report questionnaire will be used to assess HRQOL. The PedsQLTM Healthcare Satisfaction Generic Module: Parent Report will be used to assess healthcare satisfaction.

    Time frame: 1 year

  3. Rates of pilonidal disease-related complications

    Complications include physician, Emergency Department (ED), and urgent care visits, hospital admissions, and additional surgical procedures.

    Time frame: 1 year

  4. Rates of pilonidal disease-related procedures

    Procedures will include incision and drainage procedures and surgical excisions, and their respective post-operative complications

    Time frame: 1 year

  5. Rates of compliance with recommended treatment

    Proportion of patients completing the assigned treatments (laser session or hair removal at home)

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartActual
Oct 1, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Standard of Care (SOC)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Interventions Added Standard of Care (SOC)
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06406621
Responsible party
Peter Minneci (Surgeon in Chief, Nemours Children's Clinic) — Principal investigator
First posted
May 9, 2024
Start date
Oct 1, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Peter Minneci, MD
Contact
peter.minneci@nemours.org
302-333-9549
Lindsey Asti, PhD
Contact
lindsey.asti@nemours.org
302-651-5888
Peter C Minneci
principal investigator · Nemours Children's Health Delaware Valley

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion